TY - JOUR
T1 - Porous silicon as a platform for radiation theranostics together with a novel RIB-based radiolanthanoid
AU - Jakobsson, Ulrika
AU - Mäkilä, Ermei
AU - Airaksinen, Anu J.
AU - Alanen, Osku
AU - Etilé, Asenath
AU - Köster, Ulli
AU - Ranjan, Sanjeev
AU - Salonen, Jarno
AU - Santos, Hélder A.
AU - Helariutta, Kerttuli
N1 - Funding Information:
This work was supported by the Academy of Finland (grant nos. 308122, 277190, 298481, and 277423) and the European Uniońs Horizon 2020 Framework Research and InnovationProgramme under grant agreement no. 654002 (ENSAR2). Prof. H. A. Santos acknowledges financial support from the Biocentrum Helsinki, the Sigrid Jusélius Foundation (decision no. 4704580), and the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013, grant no. 310892).
Funding Information:
0is work was supported by the Academy of Finland (grant nos. 308122, 277190, 298481, and 277423) and the European Union´s Horizon 2020 Framework Research and Innovation
Funding Information:
Programme under grant agreement no. 654002 (ENSAR2). Prof. H. A. Santos acknowledges financial support from the Biocentrum Helsinki, the Sigrid Jusé Foundation (decision no. 4704580), and the European Research Council under the European Union’s Seventh Framework Programme (FP/2007–2013, grant no. 310892). We thank the local group at CERN ISOLDE and the IS528 collaboration for the technical support during the implantations. 0e SEM images were produced at the Aalto University Nano-microscopy Center (Finland), and we are grateful for the technical support and advice offered by the local team. We thank H.-K. Sihvo and A. J. Lindén (Veterinary Pathology and Parasitology, Department of Veterinary Biosciences, University of Helsinki) for the pathological evaluation of the histological samples. 0e possibility to use the microscopes at the Department of Geology, University of Helsinki, is acknowledged. We thank N. Sandler, Department of Biosciences, Åbo Akademi University, for providing access to laser diffraction measurements. We thank Dr. M. Sarparanta for the valuable comments on the manuscript.
Publisher Copyright:
© 2019 Ulrika Jakobsson et al.
PY - 2019
Y1 - 2019
N2 - Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with 159Dy at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [159Dy]THCPSi was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the process of producing radionuclide-implanted PSi particles is feasible and that the [ 159 Dy]THCPSi particles stay stable and local inside the tumor over seven days. Upon release of 159Dy from the particles, the main site of accumulation is in the skeleton, which is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the tumor and the radiolanthanoid remains embedded in the THCPSi.
AB - Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with 159Dy at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [159Dy]THCPSi was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the process of producing radionuclide-implanted PSi particles is feasible and that the [ 159 Dy]THCPSi particles stay stable and local inside the tumor over seven days. Upon release of 159Dy from the particles, the main site of accumulation is in the skeleton, which is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the tumor and the radiolanthanoid remains embedded in the THCPSi.
UR - http://www.scopus.com/inward/record.url?scp=85063499985&partnerID=8YFLogxK
U2 - 10.1155/2019/3728563
DO - 10.1155/2019/3728563
M3 - Article
C2 - 30992696
AN - SCOPUS:85063499985
SN - 1555-4309
VL - 2019
JO - Contrast Media and Molecular Imaging
JF - Contrast Media and Molecular Imaging
M1 - 3728563
ER -
